Pharma Research on Psoriasis - Identifying and Commercializing First-in-Class Innovation Report by Researchmoz.us

ResearchMoz.us includes new market research report "Frontier Pharma - Psoriasis - Identifying and Commercializing First-in-Class Innovation: Industry Size, Shares, Growth, Analysis, Trends And Forecast" to its huge collection of research reports.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
ResearchMoz

ResearchMOZ

Psoriasis - Identifying and Commercializing First-in-Class Innovation

Albany, NY (PRWEB) May 31, 2014

Psoriasis is a chronic, inflammatory disease triggered by deregulated Thymus-derived (T) cells, resulting inflammation and benign hyperplasia of keratinocytes within the skin. Manifestations of affected skin are red, thickened plaques with an overlying silver-white scale, which significantly impairs the patient’s physical and mental well-being.

View Full Report with TOC at: http://www.researchmoz.us/frontier-pharma-psoriasis-identifying-and-commercializing-first-in-class-innovation-report.html

The primary cause of psoriasis is unknown, as are the mechanisms that lead to immune cells directing inflammatory responses towards the skin. Within the lucrative autoimmune market, the psoriasis market has grown considerably due to the repositioning of all three marketed Tumor Necrosis Factor (TNF) inhibitors: Humira (adalimumab) and Enbrel (etanercept) which were originally approved for rheumatoid arthritis, and also Remicade (infliximab), the first biologic to be approved for Crohn’s disease, an autoimmune disease which largely affects the gastrointestinal system.

Table of Contents:

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 The Case for Innovation
2.1 Growing Opportunities for Biologic Products
2.2 Diversification of Molecular Targets
2.3 Innovative First-in-Class Product Developments Remain Attractive
2.4 Changes in the Clinical and Commercial Environment Will be More Favorable to Products That Target Niche Indications and Patient Populations
2.5 Innovation in Psoriasis

3 Clinical and Commercial Landscape
3.1 Disease Introduction
3.2 Epidemiology
3.3 Etiology
3.3.1 Genetic Predisposition
3.3.2 Environmental Factors
3.4 Pathophysiology
3.4.1 Keratinocytes
3.4.2 Dendritic Cells
3.4.3 T-Cells
3.4.4 Angiogenesis
3.4.5 Growth Factors.....

Browse More Pharmaceuticals related reports at: http://www.researchmoz.us/pharmaceutical-market-reports-38.html.

Related Reports:

Smart Pill Technology Market - Global Scenario, Trends, Industry Analysis, Size, Share And Forecast, 2011 - 2018

Smart pill technology is used to diagnose gastro intestinal disorders such as constipation and gastroparesis. Smart pill technology functions by providing the practitioner with information pertaining to the GI (gastrointestinal) tract such as pH, temperature and pressure. The technology comprises of a wireless capsule, a receiver worn by the patient and the computer software which analyzes and sorts the information collated. Smart pill is a nascent technology which holds immense potential in the field of medical diagnostics. The etiology for some of the gastro intestinal disorders is still unknown to us due to the limited diagnostic scope of the existent medical devices. Smart pill technology with the help of the concept - biological microelectromechanical systems will enable practitioners with a higher degree of flexibility to monitor and diagnose such clandestine and mysterious diseases. Browse Full Report at: http://www.researchmoz.us/smart-pill-technology-market-global-scenario-trends-industry-analysis-size-share-and-forecast-2011-2018-report.html

The Pharmaceutical Market: Canada

The relatively high consumption of patented drugs in Canada in comparison with other developed countries remains a positive sign for multinational pharmaceutical companies to maintain their current sales levels by 2017. Although innovative drugmakers have also experienced government cost containment policies and the patent cliff in Canada, the negative impact of these phenomena is less extreme than that in many other developed countries. The average cost of generic drugs per prescription experienced its first decline in Canada during 2011, indicating that a more competitive environment for generic drugmakers has been formed, which will ultimately benefit consumers. Browse Full Report with TOC at: http://www.researchmoz.us/the-pharmaceutical-market-canada-report.html

The Pharmaceutical Market: Central America

The political instability and underdeveloped economies in many Central American countries make the region less attractive to multinationals, compared with most neighbouring countries. However, the heavy reliance on imported medicine in the region provides revenue-generating opportunities for generic drugmakers from neighbouring Latin American countries and India. We highlight that Costa Rica and Panama can be the premier countries in the region for foreign drugmakers to expand their presence. The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors. Browse Full report with TOC at: http://www.researchmoz.us/the-pharmaceutical-market-central-america-report.html

About Us:

ResearchMoz ( http://www.researchmoz.us/ ) is the one stop online destination to find and buy market research reports. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. We provide the market context, competitor insight and future trends needed for strategic planning.

For More Information Kindly Contact:
Mrs.Sheela AK
Tel:+1-518-618-1030
Toll Free: 866-997-4948
Email: sales(at)researchmoz(dot)us
Blog: http://marketingresearchreport.wordpress.com/